Latest Intelligence on Therapy Area in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Xanthus Pharmaceuticals: trial hopes to meet unmet need in secondary leukemia

Xanthus Pharmaceuticals has begun patient dosing in a Phase III trial of its drug Xanafide. Patients with secondary acute myeloid leukemia are poorly served by existing drug therapy; physicians are therefore likely to be enthusiastic about a drug which can improve treatment outcomes. At this stage of development, however, it is too early to forecast the chances of Xanthus's drug being successful.

Published By Datamonitor
10 Oct 2007
CommentWire
CommentWire

Wyeth: yet more bad news for Pristiq

The termination of Pristiq for fibromyalgia represents another setback for Wyeth, which had high hopes for its follow-on drug to Effexor. However, all is not lost as Wyeth's greatest commercial opportunity for Pristiq will be gained through indications for depression and menopausal symptoms, although heart and liver safety concerns added to regulatory delays may still limit the drug's potential.

Published By Datamonitor
10 Aug 2007
CommentWire
CommentWire

Wyeth: WHI Premarin study stops early

The 2002 halt of the WHI study using Wyeth's [WYE] Prempro triggered heavy losses to Premarin family sales. Now the remaining study, including Premarin itself, has also come to an abrupt end due an increased risk of stroke. After losing around $1 billion of the brand's annual revenue since 2002, this slide is now unlikely to slow.

Published By Datamonitor
05 Mar 2004
CommentWire
CommentWire

Wyeth: Prempro linked with dementia

A recent study published in the Journal of the American Medical Association has shown that Wyeth's hormone combination therapy Prempro increases the risk of probable dementia in postmenopausal women aged 65 years or older. Further studies are needed to establish the role of estrogen therapies in the onset of Alzheimer's disease.

Published By Datamonitor
29 May 2003
CommentWire
CommentWire

Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor
29 Jul 2009
CommentWire
CommentWire

Wyeth: optimizing bazedoxifene's lifecycle strategy

Wyeth has received an approvable letter from the FDA which confirms that bazedoxifene, to be marketed as Viviant, is likely to be indicated for the prevention of postmenopausal osteoporosis. This is the first step in what Datamonitor expects to be a successful and maintained brand lifecycle management strategy.

Published By Datamonitor
25 Apr 2007
CommentWire
CommentWire

Wyeth: not SAD about Effexor approval

The expanding versatility of Wyeth's blockbuster Effexor is key to its continued success. Sales should top $2 billion in 2003. However, competition is strong with large players including Pfizer and GlaxoSmithKline battling for a share of the lucrative mood disorders market. Nevertheless, Effexor's advantageous mechanism of action and convenient once-daily dosage will provide the edge over rivals.

Published By Datamonitor
13 Feb 2003
CommentWire
CommentWire

Wyeth: hanging onto the osteoporosis drug discovery bandwagon

Wyeth's [WYE] pipeline is looking bare, particularly in women's health, with only two linked candidates in trials for osteoporosis/menopause. Recent agreements with biotech firms Tanox [TNOX] and Galapagos Genomics show the company is finally following other osteoporosis players' examples in a bid to remain in this lucrative market.

Published By Datamonitor
21 Nov 2003
CommentWire
CommentWire

Wyeth: Effexor XR is deemed effective

Wyeth has released the findings of the study, which pooled together results of eight double-blind studies and compared Effexor XR to a leading serotonin selective re-uptake inhibitor. Although the drug's sales should be high it could suffer at the hands of strong competition from Lilly's duloxetine.<BR />

Published By Datamonitor
13 Dec 2002
CommentWire
CommentWire

Wyeth: Effexor unsuitable for depressed children

Wyeth [WYE] has warned that its antidepressant Effexor (venlafaxine) is not effective for treating depression in children and teenagers, raising further concerns over the safety of prescribing antidepressants to children. However, due to the drug's ongoing success and growth it is unlikely this latest warning will have a significant effect on Effexor's sales.

Published By Datamonitor
08 Sep 2003

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.